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Abstract Recent reports have highlighted the anti-HIV-1 ac-
tivities of defensins, whose structure and charge resemble por-
tions of the HIV-1 transmembrane envelope glycoprotein gp41.
The current report explores the obverse, whether peptides de-
rived from HIV-1 envelope glycoproteins can exert antimicro-
bial activity. Fifteen-residue peptides spanning the entire se-
quence of HIV-1MN gp120 and gp41 were subjected to radial
di¡usion assays against laboratory strains of Escherichia coli
and Listeria monocytogenes. Twenty-four active peptides corre-
sponded predominantly to membrane-active domains of gp120
and gp41. Several peptides retained signi¢cant activity in higher
ionic conditions and may serve as templates for the development
of novel peptide antibiotics. The strategies employed herein
could uncover additional antimicrobial peptides from envelope
proteins of other lytic viruses.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Antimicrobial peptide; HIV-1; Glycoprotein;
Innate immunity; Env
1. Introduction
Antimicrobial peptides and proteins are evolutionarily
among the earliest molecular e¡ectors of innate immunity
[1]. A family of antimicrobial peptides, called defensins, are
cysteine-rich, cationic antimicrobial peptides expressed by the
leukocytes and epithelial cells of birds and mammals [2^5].
Three defensin subfamilies exist in vertebrates: K-defensins,
L-defensins, and circular (a) minidefensins [6]. All derive
from an ancestral gene that existed before reptiles and birds
diverged [7], contain six cysteines forming three stabilizing
intramolecular disul¢de bonds, and have primarily L-sheet
structures. Another major class of antimicrobial peptides in-
cludes those that are linear, cationic, and form amphipathic
K-helices upon contact with target membranes. Examples of
these peptides include mellitin from bee venom, cecropins
from moth hemolymph, and magainins from frog skin (re-
viewed in [8]).
There are a handful of reported studies on the activity of
select antimicrobial peptides against HIV-1. Tachyplesins and
polyphemusins are 17^18-residue peptides that are highly
abundant in the hemocyte debris of the Japanese (Tachypleus
tridentatus) and American (Limulus polyphemus) horseshoe
crabs, respectively [9,10]. T22, T140, and TC14012, analogs
of polyphemusin II, are highly speci¢c inhibitors of HIV-1
fusion through the antagonism of the chemokine receptor
CXCR4 [11], and thus inhibits the T cell-tropic (T-tropic;
‘X4’) strains that utilize CXCR4 as a coreceptor for entry.
Separate studies have shown that linear [12] and cyclic [13]
protegrins, peptides from porcine neutrophils that are struc-
turally similar to protegrins, are active inhibitors of HIV-1.
Another study showed that indolicidin, a 13-amino acid pep-
tide isolated from bovine neutrophils, was reproducibly viru-
cidal against HIV-1 only at very high concentrations of pep-
tide [14]. Melittin and cecropin have been found to suppress
HIV-1 gene expression [15]. Maximin 3, a linear cationic pep-
tide isolated from the skin secretions of the Chinese red belly
toad Bombina maxima, possessed modest anti-HIV activity at
low micromolar concentrations [16]. A brief report by Naka-
shima and colleagues suggested that rabbit, rat, and guinea
pig defensins can inhibit HIV-1-induced cytopathogenicity of
a CD4þ human T-cell line [17]. Although to date the antilen-
tiviral activity of human K-defensins has not been reported,
Monell and Strand have shown structural and functional sim-
ilarities between the looped motifs of K-defensins and peptides
derived from the HIV-1 gp41 envelope glycoprotein that may
be required for viral fusion and infectivity [18]. Most recently,
our group has determined that the primate circular minide-
fensins are remarkably active inhibitors of HIV-1 infection
[19].
Since defensins and certain regions of HIV-1 gp41 share
similar characteristics, including size, structure, and cationic
charge at neutral pH [18], we have chosen to study whether
peptides derived from the HIV-1MN envelope glycoproteins,
gp120 and gp41, contain defensin-like antimicrobial activity.
Precedents for these studies include several elegant reports
revealing a structural correlation between peptides from viral
transmembrane proteins and magainins, naturally occurring
amphipathic K-helical antimicrobial peptides from frogs [20^
22]. Peptides derived from the C-terminal region of gp41,
termed lentiviral lytic peptides (LLPs), are amphipathic and
cationic, and microbicidal against a broad spectrum of bac-
teria. In the current study, we test the antimicrobial activity of
peptides encompassing the entire sequence of the two enve-
lope proteins from HIV-1MN, gp120 and gp41, and determine
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regions of activity within these membrane glycoproteins that
are active against laboratory strains of Gram-positive and
Gram-negative bacteria. These studies will allow us to study
known membrane-active regions of other viral proteins to
determine regions that may be suitable for antimicrobial pep-
tide design and development. Additionally, determining mi-
crobicidal domains might better enable us to resolve structural
features of viral proteins that are crucial for interactions with
the host cell membrane.
2. Materials and methods
2.1. Reagents
A set of 212 peptides derived from HIV-1MN gp160, most of which
were 15 amino acids in length with 11-amino acid overlaps between
sequential peptides, were obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH, Be-
thesda, MD, USA (Catalog #6451). One hundred and twenty-¢ve
peptides that were soluble at 1 mg/ml in acidi¢ed water (0.01% acetic
acid) were analyzed in subsequent tests of antimicrobial activity. Pep-
tides that span the proteolytic cleavage site between gp120 and gp41
are not representative of the mature envelope glycoproteins and thus
are not reported in this study.
2.2. Microbes and culture conditions
Listeria monocytogenes strain EGD and Escherichia coli strain ML-
35p are laboratory test strains that were treated as described previ-
ously [23]. Brie£y, liquid nitrogen-frozen stationary cultures of either
strain were subcultured immediately prior to use in 50 ml 3% Trypti-
case Soy Broth (TSB; Becton Dickinson Microbiology Systems,
Sparks, MD, USA) for 2.5 h at 37‡C in an environmental shaking
incubator (250 rpm) to obtain bacteria in mid-logarithmic growth
phase. Subcultures were centrifuged at 1400Ug for 10 min, washed
in Hanks’ balanced salt solution (HBSS; Invitrogen Life Technolo-
gies, Carlsbad, CA, USA), and resuspended to the desired cell density
in HBSS. For each bacterial strain an OD625 = 1.0 was equivalent to
approximately 2.5U108 CFU/ml.
2.3. Antimicrobial assay
Radial di¡usion assays (RDAs) were performed as previously de-
scribed [24]. The underlay consisted of 1% agarose and 1:100 dilution
of TSB in either (a) 10 mM sodium phosphate, pH 7.4, (b) 10 mM
Fig. 1. HIV-1MN env (15-mer) peptides utilized in antimicrobial as-
says. Peptides were obtained from the NIH AIDS Research and
Reference Reagent Program, and those peptides that were soluble in
0.01% acetic acid are given. Shown here are the 86 peptides derived
from gp120 (A) and 39 peptides derived from gp41 (B) that were
tested for antimicrobial activity in Figs. 2 and 3. Maximum overlap
between adjacent peptides is 11 amino acids.
Table 1
Antimicrobial activity of HIV-1 peptides derived from gp120 and gp41
Protein Peptidea Structural motifb Amino acid sequence Isoelectric point E. colic L. monocytogenesc
(0) (50) (100) (0) (50) (100)
gp120 6238 n.d. PCVKLTPLCVTLNCT 8.31 33 ^ ^ ^ ^ ^
6265 loop A PAGFAILKCNDKKFS 9.26 53 ^ ^ 19 ^ ^
6269 n.d. KGSCKNVSTVQCTHG 8.90 33 16 ^ 28 ^ ^
6283 V3 VQINCTRPNYNKRKR 11.01 44 53 ^ 40 ^ ^
6284 V3 CTRPNYNKRKRIHIG 11.01 70 41 ^ 29 ^ ^
6286 V3 RKRIHIGPGRAFYTT 11.72 67 56 28 30 ^ ^
6288 V3 GRAFYTTKNIIGTIR 11.00 33 ^ ^ 34 5 ^
6289 V3 YTTKNIIGTIRAQAH 9.99 30 ^ ^ 18 ^ ^
6290 V3 NIIGTIRQAHCNISR 10.35 14 ^ ^ ^ ^ ^
6291 V3 TIRQAHCNISRAKWN 10.86 36 ^ ^ ^ ^ ^
6292 V3 AHCNISRAKWNDTLR 9.51 16 ^ ^ ^ ^ ^
6294 n.d. KWNDTLRQIVSKLKE 9.71 48 32 ^ 13 ^ ^
6295 n.d. TLRQIVSKLKEQFKN 10.29 38 23 ^ 17 ^ ^
6297 n.d. LKEQFKNKTIVFNQS 9.70 ^ ^ ^ 8 ^ ^
gp41 6350 HR1 HMLQLTVWGIKQLQA 8.76 38 ^ ^ ^ ^ ^
6351 HR1 LTVWGIKQLQARVLA 11.00 33 ^ ^ 34 6 ^
6352 HR1 GIKQLQARVLAVERY 9.99 12 ^ ^ 6 ^ ^
6359 n.d. GKLICTTTVPWNASW 8.22 18 ^ ^ ^ ^ ^
6383 MSD RIVFAVLSIVNRVRQ 12.30 37 28 20 34 29 30
6399 n.d. LRSLFLFSYHHRDLL 8.76 ^ ^ ^ 9 ^ ^
6416 LLP-1 VIEVLQRAGRAILHI 9.58 13 ^ ^ ^ ^ ^
6417 LLP-1 LQRAGRAILHIPTRI 12.30 44 ^ ^ ^ ^ ^
6418 LLP-1 GRAILHIPTRIRQGL 12.30 52 26 ^ ^ ^ ^
6419 LLP-1 LHIPTRIRQGLERAL 11.70 14 ^ ^ ^ ^ ^
aPeptide identi¢cation corresponds to reagent numbers in the NIH AIDS Research and Reference Reagent Program.
bHR1=heptad repeat region 1, which also contains a portion of the defensin-like domain; MSD=membrane-spanning domain; LLP-1= lentivi-
ral lytic peptide-1 domain; n.d. =not determined.
cResults are given as RDUs; ‘^’ denotes no activity. All tests were performed in 10 mM sodium phosphate, pH 7.4 either with no added salt
‘(0)’, 50 mM NaCl ‘(50)’, or 100 mM NaCl ‘(100)’.
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sodium phosphate/50 mM NaCl, pH 7.4 or (c) 10 mM sodium phos-
phate/100 mM NaCl, pH 7.4. Overlay consisted of 6% TSB and 1%
agarose in dH2O. Bacteria (4U106) were mixed with 10 ml of under-
lay gel solution, kept molten at 46^48‡C and poured into 100-cm2
square Petri dishes. After agarose solidi¢ed, a series of 3.2 mm diam-
eter wells were punched and 5 Wl of peptides (5.6 Wg/ml^1 mg/ml) in
0.01% acetic acid were added into designated wells. Plates were incu-
bated for 3 h at 37‡C to allow peptide di¡usion. The microbe-laden
underlay was then covered with 10 ml of molten nutritive overlay and
the plates were permitted to harden. Antimicrobial activity was iden-
ti¢ed as a clear zone around the well after 18 h incubation at 37‡C,
and represented in radial di¡usion units (RDU): [diameter of clear
zone in mm minus well diameter]U10. For some peptides, the x-in-
tercept of the relationship between zone diameter and log10 peptide
concentration was determined by least mean squares regression, and
equated to the minimal inhibitory concentration (MIC).
3. Results and discussion
We examined the antimicrobial activity of peptides from the
glycoproteins of HIV-1MN envelope because several distinct
regions of the glycoproteins are membrane-active and have
similar properties to known antimicrobial peptides, such as
small size and high local cationic charge at neutral pH. Two
hundred and twelve 15-residue peptides with 11-amino acid
overlaps between sequential peptides were obtained from the
NIH Research and Reference Reagent Program. Peptides that
were fully soluble in 0.01% acetic acid (acidi¢ed water) are
represented in Fig. 1, and span approximately 95.0% of the
sequence of gp120 (86 peptides; Fig. 1A) and 79.0% of the
sequence of gp41 (39 peptides; Fig. 1B). Peptides that could
not be dissolved in acidi¢ed water were not tested in subse-
quent assays, contained a high proportion of hydrophobic
amino acids and coincided with regions of minimal exposure
to the protein surface.
In an initial screen, each 15-residue peptide was subjected to
radial di¡usion assays in 10 mM sodium phosphate, pH 7.4,
against E. coli and L. monocytogenes and the activity was
given as RDU, a measure of di¡usible antimicrobial activity
(Figs. 2 and 3). The activity of peptides that overlapped a
particular residue is expressed as the average RDU for that
residue. Fourteen of 86 peptides from gp120 and 10 of 39
peptides from gp41 demonstrated activity against one or
both strains of bacteria (Table 1). Peptides that were deter-
mined to be antimicrobial in the initial screen were subse-
quently tested at higher salt concentrations (Table 1). There
was a precipitous drop in antimicrobial activity at increased
salt concentrations for most peptides tested. At near-physio-
logic electrolyte conditions (10 mM sodium phosphate, pH
7.4+100 mM NaCl), only two peptides remained active:
#6286 and #6383, corresponding to the immunogenic tip of
the V3 loop (containing the L-turn GPGR motif) of gp120
and the membrane-spanning domain of gp41, respectively.
The MICs for the three most active peptides are given in
Table 2.
Most of the peptides determined to exert antimicrobial ac-
tivity were derived from several areas of gp120 and gp41 that
Fig. 2. RDAs demonstrate antimicrobial activity of peptides derived
from HIV-1MN gp120. Using RDAs the antimicrobial activity of
5 Wg of each 15-residue peptide derived from gp120 was tested sepa-
rately in 10 mM sodium phosphate, pH 7.4, against E. coli (top
panel) and L. monocytogenes (middle panel). Activity is expressed as
RDU, which are a measure of the di¡usible peptide activity. The
ExPASy program, ProtScale (http://expasy.cbr.nrc.ca/cgi-bin/protsca-
le.pl) was used to plot the charged residue pro¢le of gp120 (bottom
panel). Note that peptides in regions of gp120 with a high net posi-
tive charge were antimicrobial. Regions of gp120 that were tested
by RDA are represented by thick lines, and untested regions are
represented by thin lines.
Fig. 3. RDAs demonstrate antimicrobial activity of peptides derived
from HIV-1MN gp41. Using RDAs the antimicrobial activity of 5 Wg
of each 15-residue peptide derived from gp41 was tested separately
in 10 mM sodium phosphate, pH 7.4, against E. coli (top panel)
and L. monocytogenes (middle panel). Activity is expressed as RDU,
which are a measure of the di¡usible peptide activity. ProtScale was
used to plot the charged residue pro¢le of gp41 (bottom panel).
Peptides in regions of gp41 with a high net positive charge were
antimicrobial. Regions of gp41 that were tested by RDA are repre-
sented by thick lines, and untested regions are represented by thin
lines.
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have been previously described as membrane-active. Within
gp120, the entire V3 region, a disul¢de-constrained surface-
exposed loop encoded by a variable region of env [25], and
exposed regions £anking V3 (Fig. 4) were potently active. The
determinants of HIV-1 usage of chemokine coreceptors
(CXCR4 and/or CCR5) for viral attachment and entry pri-
marily reside within the V3 hypervariable region [26^29]. The
V3 loop is critical for HIV-1 infection of cells that lack CD4,
the primary receptor of gp120, and instead can utilize galac-
tosylceramide on the host cell membrane as an alternative
receptor for viral entry [30^32]. Many antimicrobial peptides
exert their activity against microbes through a process involv-
ing an initial electrostatic binding of peptide to the surface of
microbial membranes (reviewed in [33]). Events that interfere
with the electrostatic peptide^membrane interaction nega-
tively in£uence downstream events including peptide inser-
tion, membrane pore formation and microbial lysis. The ini-
tial binding step involves interactions between basic residues
of the antimicrobial peptide and electronegative regions of
bacterial lipopolysaccharide and/or peptidoglycan. Subse-
quently, insertion will lead to interaction between the peptides
and the anionic lipid moieties of the target microbe, and is
thus highly dependent on the cationicity of the peptide. It is
therefore not surprising that the net cationic charge of the 35-
residue V3 loop is highly basic (pI 11.01), as were active pep-
tides derived from this region (Table 1). The activity of the V3
loop may be a combination of its cationic character and its
ability to bind carbohydrate moieties.
The most active peptide (#6383) originated from the viral
membrane-spanning domain of gp41. Indeed, this was the
only peptide that retained activity against both E. coli and
L. monocytogenes at the highest salt concentrations tested
(10 mM sodium phosphate, pH 7.4+100 mM NaCl). The
other two domains of gp41 that were appreciably antimicro-
bial include the N-terminal heptad repeat region (Fig. 4),
which encompasses a portion of the defensin-like domain
[18], and the C-terminal tail from which LLPs were derived
[20^22]. Synthetic peptides corresponding to either the N-ter-
minal (e.g. T21) or C-terminal (e.g. T20) heptad repeat re-
gions of gp41 are inhibitors of HIV-1 entry [34^36] and are
currently under development as therapeutics (reviewed in
[37]). Our ¢ndings suggest that entry inhibitor therapeutics
corresponding to the N-terminal heptad repeat region would
have an additional bene¢t of antibacterial activity.
While the activity of peptide #6383 can be partially ex-
plained by its high isoelectric point (pI 12.30), other peptides
with identical pIs, such as #6417 and #6418, were not active
at higher salt concentrations and were not active against
Fig. 4. Structural orientation of antimicrobial regions on the core of gp120 and gp41. A: A model of core gp120 (PDB accession code: 1G9M
[40]) was drawn using the Swiss PDB Viewer (http://www.expasy.ch/spdbv/mainpage.html), and colored red to indicate regions of antimicrobial
activity. Non-active regions of gp120 are colored gray (connections), green (helices), and blue (L-sheets). The disordered V4 loop is shown by a
dashed line. As described in [40], the viral membrane is oriented above gp120, the target membrane is below, and the C-terminal tail of CD4
would be behind the molecule going into the page. B: A model of a monomer of N51 (dark green) and C43 (light green) of the gp41 core
(PDB accession code: 1AIK [41]) was drawn using the Swiss PDB Viewer, and colored red to indicated regions of antimicrobial activity. Note
that the active region in red corresponds to a segment of the N-terminal heptad repeat region, HR-1.
Table 2
MICs of peptides derived from gp120 and gp41a
Peptide EC(0) (Wg/ml) EC(50) (Wg/ml) EC(100) (Wg/ml) LM(0) (Wg/ml) LM(50) (Wg/ml) LM(100) (Wg/ml)
6284 5.47X2.72 28.7X 18.2 n.t. 10.7 X 0.56 n.t. n.t.
6286 2.33X0.24 18.1X 11.6 92.8X 73.8 26.0X 14.5 s 250 s 250
6383 0.5050.20 4.875 1.64 2.7350.56 0.665 0.17 1.975 0.32 3.105 1.20
an=3 experiments for each condition; n.t. denotes not tested. EC=E. coli ; LM=L. monocytogenes. All tests were performed in 10 mM sodium
phosphate, pH 7.4 either with no added salt ‘(0)’, 50 mM NaCl ‘(50)’, or 100 mM NaCl ‘(100)’. Range of peptides used to extrapolate
MIC=3.9^500 Wg/ml.
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L. monocytogenes (Table 1). Even though high net positive
charge is a primary determinant of microbicidal activity, other
structural features also in£uence activity. Nevertheless, pep-
tides such as #6383 that are active in high ionic conditions
would serve as good templates for the design of antimicrobials
active in diseases where the salt concentrations have been
reportedly elevated, including the airways of patients with
cystic ¢brosis [38,39]. In addition, the strategy employed here-
in to determine a protein’s antimicrobially active regions
should be extended to envelope proteins from other lytic vi-
ruses, and might be bene¢cial in elucidating structures that
interact with membrane targets.
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